GSK2982772
|
- ₹0
- Product name: GSK2982772
- CAS: 1622848-92-3
- MF: C20H19N5O3
- MW: 377.4
- EINECS:
- MDL Number:MFCD30489467
- Synonyms:(S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide;5184;GSK2982772;RIP1 inhibitor GS2982772;CS-2502;(S)-5-BENZYL-N-(5-METHYL-4-OXO-2,3,4,5-TETRAHYDROBENZO[B][1,4]OXAZEPIN-3-YL)-4H-1,2,4-TRIAZOLE-3-CAR;GSK 2982772;GSK-2982772;1H-1,2,4-Triazole-5-carboxamide, 3-(phenylmethyl)-N-[(3S)-2,3,4,5-tetrahydro-5-methyl-4-oxo-1,5-benzoxazepin-3-yl]-
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|
Properties
Density :1.40±0.1 g/cm3(Predicted)
storage temp. :-20°C
solubility :Soluble in DMSO (>25 mg/ml)
form :solid
pka :8.80±0.40(Predicted)
color :Off-white
Stability :Stable for 2 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 1 month.
storage temp. :-20°C
solubility :Soluble in DMSO (>25 mg/ml)
form :solid
pka :8.80±0.40(Predicted)
color :Off-white
Stability :Stable for 2 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 1 month.
Safety Information
| Symbol(GHS): |
|
|||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal word: | Warning | |||||||||||||||||||||||||||||||||||
| Hazard statements: |
|
|||||||||||||||||||||||||||||||||||
| Precautionary statements: |
|
Description
(S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide, also known as GSK2982772, is a first-in-class receptor interacting protein 1(RIP1)-kinase specific clinical candidate for the treatment of inflammatory disease. It is an inhibitor of RIP1 that regulates necroptosis and inflammation and may play an important role in contributing to a variety of human pathologies, including immune-mediated inflammatory diseases. It has excellent activity in blocking many TNF-dependent cellular responses. Highlighting its potential as a novel anti-inflammatory agent, the inhibitor was also able to reduce spontaneous production of cytokines from human ulcerative colitis explants.More related product prices
6-[(1-acetylpiperidin-4-yl)amino]-N-[(2S)-2-hydroxy-3-(1,2,3,4-tetrahydroisoquinolin-2-yl)propyl]pyrimidine-4-carboxamide GSK-2881078 GSK2636771 MethanesulfonaMide, N-[5-[4-[5-[[(2R,6S)-2,6-diMethyl-4-Morpholinyl]Methyl]-2-oxazolyl]-1H-indazol-6-yl]-2-Methoxy-3-pyridinyl]-, rel- N-(4-ethylphenyl)-3-(hydroxymethyl)-N-isobutyl-4-((tetrahydro-2H-pyran-4-yl)methoxy)benzenesulfonamide cyclopentyl 2-cyclohexyl-2-((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl)methylamino)acetate 864082-47-3 GSK-2256098 GSK 2334470 GSK J4 HCl 1346574-57-9 GSK2837808A 942206-85-1 GSK484 GSK864 GSK6853 GSK 2033Related product price
- GSK 2334470
₹16672.2-67099.5 - GSK J4 HCl
₹11677.2-47552.4 - 942206-85-1
₹28491.4-111053.68
